Abstract 882P
Background
While strong evidence indicates quitting smoking reduces the risk of developing head and neck cancer (HNC), it remains unclear whether patients who smoke could still benefit from quitting after HNC diagnosis. We investigated the impact of postdiagnosis smoking cessation on the survival of patients with HNC who smoked at diagnosis.
Methods
This prospective study included 1,298 participants who were diagnosed with HNC in the United Kingdom (Head and Neck 5000 study, recruitment: 2011-2014), and 4 countries in Latin America (Brazil, Argentina, Uruguay, and Colombia - INTERCHANGE study, recruitment: 2011-2017) who actively smoked at diagnosis. Participants have been actively followed since their diagnosis to collect regular information on their smoking behavior and disease status. Overall survival was evaluated using extended Kaplan-Meier curves and time-dependent Cox proportional hazards regression models.
Results
During the follow-up, 442 participants (34%) reported quitting smoking, and 571 deaths were recorded. Median survival time was 17 months higher when patients quit vs. continued smoking (median survival time = 6.6 vs. 5.2 years, p<0.001). At 5-years, the survival rate was significantly higher when patients quit vs. continued smoking (61.0% vs. 50.6%, p<0.001). After accounting for the quitting time and adjusting for potential confounders, quitting smoking was associated with 33% lower risk of death compared to continued smoking (HR=0.67, 95%CI=0.56-0.81). Stratified analyses revealed consistent survival benefits associated with quitting smoking among all patient subgroups, including those who reported mild-moderate vs. heavy smoking, and patients who were diagnosed with earlier vs. later-stage tumors. The benefits of quitting smoking were also evident across various HNC subtypes.
Conclusions
Quitting smoking after HNC diagnosis may significantly reduce the risk of death and improve survival among patients who smoke. These findings underscore the importance of post-diagnosis smoking cessation interventions as part of comprehensive cancer care for HNC patients.
Clinical trial identification
Editorial acknowledgement
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
890P - Stereotactic body radiation therapy combined with chemotherapy and tislelizumab in metastatic nasopharyngeal carcinoma: A prospective, single-arm, phase II study
Presenter: Tongxin Liu
Session: Poster session 02
891P - Pembrolizumab and olaparib in recurrent/metastatic, platinum resistant nasopharyngeal cancer: The POINT study
Presenter: Cristina Gurizzan
Session: Poster session 02
892P - Camrelizumab plus dalpiciclib in anti-PD-1 refractory recurrent or metastatic nasopharyngeal carcinoma
Presenter: Xi Ding
Session: Poster session 02
894P - AXEL: AXitinib-avELumab combination in recurrent or metastatic (RM) nasopharyngeal cancer (NPC)
Presenter: Edwin Hui
Session: Poster session 02
895P - Cost effectiveness of stereotactic ablative radiotherapy (SABR) alone in comparison with systemic treatment and SABR in oligometastatic head and neck cancer in the GORTEC 2014-04 OMET randomized phase II study
Presenter: Juliette Thariat
Session: Poster session 02
896P - Day of the week of chemotherapy (CT) during concurrent chemoradiation (CRT) for oropharyngeal squamous cell carcinoma (OPSCC)
Presenter: Camilla Hoff
Session: Poster session 02
897P - Tumor habitat-based MRI features assessing early response in locally advanced nasopharyngeal carcinoma
Presenter: Jinling Yuan
Session: Poster session 02
898P - Real-world overall survival (OS) in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC) in Asia: A literature review
Presenter: Darren Wan-Teck Lim
Session: Poster session 02
899P - Safety and efficacy of a novel CAR-T cell therapy (BRG01) targeting the Epstein-Barr Virus envelope glycoprotein in advanced metastatic nasopharyngeal cancer patients
Presenter: Li Zhang
Session: Poster session 02